Science, innovation and commitment

Psychosocial and psychological interventions reduce relapse risk in schizophrenia

Dr. Helena García-Mieres from the IRSJD has collaborated in an international study, led by researchers from the Technical University of Munich and the University of Catania, which has analyzed the results of different studies on relapses in schizophrenia to check the efficacy of psychological and psychosocial interventions for its relapse prevention.

Josep Maria Haro and Ai Koyanagi among the most influential researchers worldwide

According to the ranking of the innovation company Clarivate Analytics, Dr. Ai Koyanagi and Dr. Josep Maria Haro are among the hundred most prominent experts who work in the Spanish State and lead projects with an international impact.

Gate2Brain receives funding from ”la Caixa” Foundation to accelerate its transfer to the market and society

Gate2Brain, a spin-off of Sant Joan de Déu (SJD), Institute for Research in Biomedicine (IRB) Barcelona and University of Barcelona (UB) will develop a new drug using a shuttle peptide that crosses the blood-brain barrier (BBB) to improve treatments for pediatric brain cancer.

Study reveals that a high percentage of children and adolescents with early onset psychosis suffer from clinical depression

A study carried out by researchers from the Institut Sant Joan de Déu and the Parc Sanitari Sant Joan de Déu reveals that a high percentage of children and adolescents with early onset psychosis suffer from clinical depression. The article has been published in the scientific journal European Child & Adolescent Psychiatry.

Agenda

#NeuroConCiencia · Centre Imatge Pediátrica Computacional a SJD

Speaker: Josep Munuera, PhD

Online

08:00h

#SeminarIRSJD · Ciència i COVID-19. Una perspectiva multidisciplinària

Speaker: Clara Prats, PhD. Researcher in BIOCOM-UPC

Online

15:30h

Interviews

Alexandra Avgustinova

Group leader · Paediatric Tumour Epigenetics Group

“We approach the study of paediatric tumours from different angles with the ultimate goal of developing more personalised and less aggressive treatments”

Read more More Interviews